On the other hand, it might be beneficial for some patients to use anti-RANTES therapy as maraviroc, and to use other compounds discovered in this class which affect the CCR5, the main ligand for RANTES, resulting in, e.g., decreasing cellular proliferation, inducing of apoptosis by arresting cells in the G0/G1 phase, and decreasing cellular migration of the colorectal cancer cells [44]. The gene discussed is CCL5; the disease is colorectal cancer.